Elicio Therapeutics, Inc. entered into an At Market Issuance Sales Agreement on March 16, 2026, with B. Riley Securities, Inc., JonesTrading Institutional Services LLC, and Ladenburg Thalmann & Co. Inc. to issue and sell up to $100.0 million of common stock through an at-the-market offering program. The company simultaneously terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had a $40.0 million capacity and no termination penalties.
Key takeaways
Entered At Market Issuance Sales Agreement on 2026-03-16 with Agents: B. Riley Securities, Inc., JonesTrading Institutional Services LLC, Ladenburg Thalmann & Co. Inc.
Aggregate offering price up to $100.0 million of common stock (par value $0.01 per share)
Agents receive 3.0% commission on gross sales proceeds
Terminated prior JonesTrading Capital on Demand Sales Agreement (entered June 3, 2024, up to $40.0 million) effective 2026-03-16 with no penalties
Sales pursuant to Form S-3 Registration Statement (File No. 333-293861)